Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For all parts of the trial:
- Men aged 18 or older
- People whose prostate cancer has been confirmed by laboratory testing of tissue or cell samples
- People whose blood counts, kidney function, and liver function are at adequate levels
- People who are able to swallow tablets or capsules
For the advanced prostate cancer arms (mCRPC – certain phases):
- People who have had their testicles surgically removed, or who are receiving ongoing hormone-blocking therapy, and have very low testosterone levels as a result
- People whose prostate cancer has continued to worsen, shown by rising PSA levels, despite their most recent treatment
For the SOAR arm (Phase 2 Part 2A):
- People with hormone-sensitive prostate cancer that has spread to distant parts of the body, confirmed by standard imaging
- People with a PSA level of 0.2 ng/mL or higher, after receiving a specific type of hormone therapy (called an ARPI) for between 180 and 365 days
- People who have not shown signs of cancer progression on imaging or through PSA levels while receiving that hormone therapy
For the hormone-sensitive advanced prostate cancer arms (Phase 2 Parts 2B, 2C, and 2D):
- People with testosterone levels above 150 ng/mL
- People with hormone-sensitive prostate cancer that has spread to distant parts of the body, confirmed by standard imaging, and a PSA level above 2.0 ng/mL
Who may not be able to join:
For all parts of the trial:
- People who have had a recent serious bleeding event, or who have a known bleeding disorder
- People whose cancer includes a specific tumour type called neuroendocrine or small cell carcinoma (confirmed by tissue testing)
- People who are taking corticosteroid medication continuously at a dose above the equivalent of 10 mg per day of prednisone
- People who have a significant ongoing or prior serious medical condition
For the advanced prostate cancer arms (mCRPC – certain phases):
- People who have received systemic cancer treatments or experimental drugs within 2 weeks before starting the trial (some treatments may require an even longer gap before joining — confirm with trial site)
For the SOAR arm (Phase 2 Part 2A):
- People who have previously received chemotherapy for prostate cancer
For the hormone-sensitive advanced prostate cancer arms (Phase 2 Parts 2B, 2C, and 2D):
- People whose cancer has only spread to lymph nodes in the pelvic region, without more distant spread
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Frequency of dose-limiting toxicities (DLTs); Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline; Phase 1 Part 2 (formulation exploration) relative bioavailability
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.